Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Needham has reaffirmed its Buy rating on Arcellx (NASDAQ:ACLX) and increased its price target from $65.00 to $71.00, implying a potential upside of 29.78% from the current share price of $54.71. Arcellx is a clinical-stage biotech company focused on developing cell therapies for cancer and other diseases.
January 04, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham maintains a Buy rating on Arcellx with an increased price target from $65 to $71, suggesting a significant upside from the current price.
The reaffirmation of a Buy rating and an increased price target by a reputable analyst firm like Needham typically instills confidence in investors and can lead to a short-term positive impact on the stock price. The significant potential upside of 29.78% from the current price level may attract investor interest and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100